Reports Q3 revenue $80.3M, consensus $80.32M. “Third quarter sales reflect our leadership in lens-based refractive surgery and progress advancing our strategic priorities,” said Tom Frinzi, President and CEO of STAAR Surgical. “Our global ICL sales growth of 13% in the third quarter significantly outperformed industry procedure growth, which was negative in many markets around the world with the exception of China.2 Further, we are mindful of the potential impact the uncertain economic environment globally and world events may have on our surgeon customers and patients. As a result, we now expect fiscal 2023 ICL sales to be at the low end of our previously provided range of $320 million to $325 million.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STAA:
- STAA Earnings this Week: How Will it Perform?
- Staar Surgical price target lowered to $58 from $65 at Mizuho
- Fly Insider; STAAR Surgical, Blade Air among week’s notable insider trades
- Insider Trading: Staar Surgical’s (NASDAQ:STAA) Major Insider on a Buying Spree
- Needham medtech/diagnostics analysts hold analyst/industry conference call